LONDON (ShareCast) - (Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on commercial strategy, business development and market access.
Hughes would join both the management team and the business development committee.

The AIM-traded firm said he would bring extensive experience in commercial strategy and market access from senior roles at PharmaVentures, Mundipharma and Pfizer.

At Mundipharma, he led commercial launch planning for pipeline assets, while at Pfizer he worked on global pricing and access strategies across various disease areas.

He holds an MSc in public health and health economics from the London School of Hygiene and Tropical Medicine.

Faron, which is developing next-generation immunotherapies, said Hughes' appointment was made at a pivotal time, as it advanced its clinical pipeline and looked to expand partnerships.

Chief executive officer Dr Juho Jalkanen said Hughes' leadership and track record aligned closely with Faron's strategic growth plans.

At 1047 BST, shares in Faron Pharmaceuticals were up 2.71% at 227p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE